Can inflammatory cytokine signaling reduce endothelial nitric oxide synthase activity and nitric oxide bioavailability?

Inflammatory cytokines are biologically plausible contributors to endothelial dysfunction, including in older adults, through both reduced nitric-oxide (NO) production and increased oxidative loss of NO. The overall evidence supports this direction of effect with moderate confidence, although responses vary by cytokine, endothelial model, and stimulus.

Clinical and mechanistic evidence

• IL-6 can impair eNOS regulation and NO generation. In endothelial models, IL-6 reduces activating eNOS Ser1177 phosphorylation, increases inhibitory caveolin-1–eNOS interaction, and can reduce eNOS expression. These changes occur alongside lower NO release.

• TNF-α can suppress stimulus-dependent eNOS activity. Experimental evidence shows inhibition of eNOS activity and NO release, including blunted flow- and insulin-stimulated Akt/eNOS phosphorylation. However, TNF-α has also increased PI3K/Akt-linked eNOS phosphorylation and NO production in some human endothelial-cell conditions, underscoring substantial context dependence.

Oxidative mechanisms

• Cytokine-associated reactive oxygen species can further deplete NO. IL-1β has been linked to endothelial NADPH-oxidase activation and reactive-oxygen-species production. Superoxide directly scavenges NO and favors peroxynitrite formation, reducing biologically available NO even when some enzymatic production remains.

• Oxidative stress may also promote eNOS uncoupling, shifting the enzyme toward superoxide rather than NO production. Direct evidence tying IL-6 or IL-1β to BH4-dependent uncoupling in the same endothelial models is not established in the available findings.

Human relevance

• In older populations, higher circulating CRP and IL-6 are associated with poorer NO-dependent endothelial function, though these relationships weaken after accounting for conventional cardiovascular risk factors. Direct vascular-tissue evidence in aging humans remains limited.

Bottom line

• Inflammatory cytokine signaling can reduce eNOS activity and NO bioavailability, most convincingly through IL-6-related impairment of eNOS activation/expression and cytokine-associated NADPH-oxidase/ROS-mediated NO loss. The effect is mechanistically credible but not uniform across inflammatory contexts.